Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Summary
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including BCMA, with CAR-NK cells in multiple myeloma. To further investigate the potential of BCMA-targeted CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard therapy.
Timeline
- Start
- 2024-04-30
- Primary completion
- 2026-04-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-BCMA CAR-NK | Cell therapy | 1e+07 cells/kg | — |
| Subject | Anti-BCMA CAR-NK | Cell therapy | 5e+07 cells/kg | — |
| Subject | Anti-BCMA CAR-NK | Cell therapy | 1e+08 cells/kg | — |